BR112016014824A2 - Método para purificar anticorpo que tem ponto isoelétrico baixo - Google Patents
Método para purificar anticorpo que tem ponto isoelétrico baixoInfo
- Publication number
- BR112016014824A2 BR112016014824A2 BR112016014824A BR112016014824A BR112016014824A2 BR 112016014824 A2 BR112016014824 A2 BR 112016014824A2 BR 112016014824 A BR112016014824 A BR 112016014824A BR 112016014824 A BR112016014824 A BR 112016014824A BR 112016014824 A2 BR112016014824 A2 BR 112016014824A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- low
- isoelectric point
- found
- low isoelectric
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000010306 acid treatment Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 239000003957 anion exchange resin Substances 0.000 abstract 1
- 238000004587 chromatography analysis Methods 0.000 abstract 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 239000011347 resin Substances 0.000 abstract 1
- 229920005989 resin Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
MÉTODO PARA PURIFICAR ANTICORPO QUE TEM PONTO ISOELÉTRICO BAIXO. Os presentes inventores descobriram que a agregação adicional de anticorpo de baixo pH pode ser suprimida através da remoção formada, depois o anticorpo agregado tem algum período de tempo após a Proteína A purificação em coluna, o tratamento ácido, e neutralização. Além disso, os presentes inventores verificaram que a remoção de impurezas eficientes para um anticorpo de pH baixo pode ser realizado utilizando uma resina de troca aniônica no BIND / moda eluir e depois uma cromatografia de interacção hidrofóbica ou cromatografia em resina multimodal, em comparação com métodos convencionais.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013271613 | 2013-12-27 | ||
PCT/JP2014/084671 WO2015099165A1 (ja) | 2013-12-27 | 2014-12-26 | 等電点の低い抗体の精製方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016014824A2 true BR112016014824A2 (pt) | 2017-09-19 |
Family
ID=53479003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016014824A BR112016014824A2 (pt) | 2013-12-27 | 2014-12-26 | Método para purificar anticorpo que tem ponto isoelétrico baixo |
Country Status (16)
Country | Link |
---|---|
US (1) | US10654933B2 (pt) |
EP (1) | EP3088411A4 (pt) |
JP (1) | JP6722455B2 (pt) |
KR (1) | KR102344170B1 (pt) |
CN (1) | CN106029682B (pt) |
AU (1) | AU2014370873B2 (pt) |
BR (1) | BR112016014824A2 (pt) |
CA (2) | CA3233584A1 (pt) |
IL (3) | IL296754A (pt) |
MX (2) | MX2016008498A (pt) |
MY (1) | MY181081A (pt) |
NZ (1) | NZ722057A (pt) |
RU (1) | RU2714967C2 (pt) |
SG (1) | SG11201605256YA (pt) |
TW (2) | TWI715524B (pt) |
WO (1) | WO2015099165A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017022651A1 (ja) * | 2015-07-31 | 2017-02-09 | 中外製薬株式会社 | アニオン性ポリマーによる抗体を含有する組成物の精製方法 |
MY197200A (en) | 2016-12-23 | 2023-05-31 | Serum Institute Of India Pvt Ltd | Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof |
US10899844B2 (en) * | 2017-02-08 | 2021-01-26 | Novartis Ag | FGF21 mimetic antibodies and uses thereof |
US11945839B2 (en) * | 2017-12-22 | 2024-04-02 | Hoffmann-La Roche Inc. | Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography |
KR102337683B1 (ko) * | 2018-09-21 | 2021-12-13 | 주식회사 녹십자 | 고효율 항-tfpi 항체 조성물 |
CN114181300A (zh) * | 2021-12-20 | 2022-03-15 | 方坦思(上海)生物医药有限公司 | 一种高纯度单克隆抗体的制备方法 |
CN116769044A (zh) * | 2023-07-11 | 2023-09-19 | 康日百奥生物科技(苏州)有限公司 | 抗cd3和cd19双特异性抗体蛋白及其层析纯化方法 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4891312A (en) * | 1986-08-13 | 1990-01-02 | Monsanto Company | Monoclonal antibody specific for human colon fibroblast-derived t-PA |
JPS63149900A (ja) | 1986-12-15 | 1988-06-22 | Toshiba Corp | 半導体メモリ |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CA2109602C (en) | 1990-07-10 | 2002-10-01 | Gregory P. Winter | Methods for producing members of specific binding pairs |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
GB9022547D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Purified immunoglobulin |
ES2134212T3 (es) | 1991-04-25 | 1999-10-01 | Chugai Pharmaceutical Co Ltd | Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano. |
EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
ATE463573T1 (de) | 1991-12-02 | 2010-04-15 | Medimmune Ltd | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
JP3507073B2 (ja) | 1992-03-24 | 2004-03-15 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的結合対の成員の製造方法 |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
CA2160224A1 (en) | 1993-04-09 | 1994-10-27 | David B. Ring | Bispecific antigen-binding molecules |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
DE69535243T2 (de) | 1994-07-13 | 2007-05-10 | Chugai Seiyaku K.K. | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク. | 免疫したゼノマウス(XenoMouse)に由来するヒト抗体 |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
RU2198220C2 (ru) | 1996-09-26 | 2003-02-10 | Чугаи Сейяку Кабусики Кайся | Антитело против белка, родственного паращитовидному гормону человека, днк, вектор, способ получения и использование антитела |
UA76934C2 (en) | 1996-10-04 | 2006-10-16 | Chugai Pharmaceutical Co Ltd | Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody |
PL343322A1 (en) | 1998-04-03 | 2001-08-13 | Chugai Pharmaceutical Co Ltd | Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody |
TWI241345B (en) | 2000-03-10 | 2005-10-11 | Chugai Pharmaceutical Co Ltd | Apoptosis inducing polypeptide |
AU2002210917B2 (en) | 2000-10-20 | 2006-05-18 | Chugai Seiyaku Kabushiki Kaisha | Degraded TPO agonist antibody |
EP2204190A1 (en) | 2003-07-15 | 2010-07-07 | Chugai Seiyaku Kabushiki Kaisha | IgM production by transformed cells and methods for quantifying said IgM production |
CN102276717B (zh) * | 2003-10-27 | 2015-09-09 | 惠氏公司 | 使用羟磷灰石层析除去高分子量聚集体 |
WO2005077130A2 (en) | 2004-02-11 | 2005-08-25 | Tanox, Inc. | A method for the removal of aggregate proteins from recombinant samples using ion exchange chromatography |
DK3056568T3 (da) | 2006-03-31 | 2021-11-01 | Chugai Pharmaceutical Co Ltd | Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik |
US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
BRPI0811857A2 (pt) | 2007-05-14 | 2014-10-21 | Biogen Idec Inc | Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados. |
PL2188306T3 (pl) * | 2007-08-10 | 2017-01-31 | Janssen Biotech, Inc. | Fragmenty powstałe po cięciu immunoglobuliny jako wskaźniki choroby oraz kompozycje do ich wykrywania i wiązania |
CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
KR101561314B1 (ko) | 2007-09-26 | 2015-10-16 | 추가이 세이야쿠 가부시키가이샤 | 항il-6 수용체 항체 |
CN101874041B (zh) | 2007-09-26 | 2013-06-19 | 中外制药株式会社 | 抗体恒定区修饰体 |
ES2585480T3 (es) | 2007-12-05 | 2016-10-06 | Chugai Seiyaku Kabushiki Kaisha | Anticuerpo anti-NR10 y uso del mismo |
PE20140852A1 (es) * | 2008-07-18 | 2014-07-14 | Bristol Myers Squibb Co | Composiciones monovalentes para union a cd28 |
JP2010041761A (ja) * | 2008-07-31 | 2010-02-18 | Thk Co Ltd | リニアモータ |
SG10201702922VA (en) * | 2008-10-20 | 2017-06-29 | Abbvie Inc | Isolation and purification of antibodies using protein a affinity chromatography |
AU2009307737B2 (en) * | 2008-10-20 | 2015-07-23 | Abbvie Inc. | Viral inactivation during purification of antibodies |
SG10201900451SA (en) | 2009-03-19 | 2019-02-27 | Chugai Pharmaceutical Co Ltd | Pharmaceutical formulation containing improved antibody molecules |
JP5721204B2 (ja) * | 2009-04-09 | 2015-05-20 | 旭化成ケミカルズ株式会社 | アニオン交換基が固定された多孔膜を用いた抗体モノマーの精製方法 |
DK2538976T3 (en) * | 2010-02-24 | 2017-02-27 | Immunogen Inc | IMMUNCONJUGATES AGAINST FOLATRECEPTOR-1 AND APPLICATIONS THEREOF |
CN103339507A (zh) * | 2010-08-26 | 2013-10-02 | 霍夫曼-拉罗奇有限公司 | DCC第五纤连蛋白III型域的重组Fc融合蛋白 |
JP6023715B2 (ja) * | 2010-10-11 | 2016-11-09 | アッヴィ・バハマズ・リミテッド | タンパク質の精製方法 |
CN105399831A (zh) * | 2010-10-29 | 2016-03-16 | 伊缪诺金公司 | 非拮抗性egfr结合分子及其免疫偶联物 |
CA2816558C (en) * | 2010-11-19 | 2020-12-29 | Morphosys Ag | A collection and methods for its use |
WO2012135912A1 (en) * | 2011-04-05 | 2012-10-11 | Resmed Limited | Respiratory breathing apparatus |
WO2013012022A1 (ja) * | 2011-07-19 | 2013-01-24 | 中外製薬株式会社 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
AU2012355356B2 (en) * | 2011-12-22 | 2017-10-12 | Genentech, Inc. | Ion exchange membrane chromatography |
TWI593705B (zh) | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
-
2014
- 2014-12-26 MY MYPI2016702332A patent/MY181081A/en unknown
- 2014-12-26 CA CA3233584A patent/CA3233584A1/en active Pending
- 2014-12-26 TW TW103145886A patent/TWI715524B/zh active
- 2014-12-26 JP JP2015555068A patent/JP6722455B2/ja active Active
- 2014-12-26 MX MX2016008498A patent/MX2016008498A/es unknown
- 2014-12-26 KR KR1020167020075A patent/KR102344170B1/ko active IP Right Grant
- 2014-12-26 TW TW109108557A patent/TWI787590B/zh active
- 2014-12-26 CN CN201480076437.1A patent/CN106029682B/zh active Active
- 2014-12-26 AU AU2014370873A patent/AU2014370873B2/en active Active
- 2014-12-26 BR BR112016014824A patent/BR112016014824A2/pt not_active Application Discontinuation
- 2014-12-26 CA CA2935143A patent/CA2935143C/en active Active
- 2014-12-26 US US15/108,017 patent/US10654933B2/en active Active
- 2014-12-26 SG SG11201605256YA patent/SG11201605256YA/en unknown
- 2014-12-26 WO PCT/JP2014/084671 patent/WO2015099165A1/ja active Application Filing
- 2014-12-26 RU RU2016130664A patent/RU2714967C2/ru active
- 2014-12-26 IL IL296754A patent/IL296754A/en unknown
- 2014-12-26 EP EP14874295.0A patent/EP3088411A4/en active Pending
- 2014-12-26 NZ NZ722057A patent/NZ722057A/en unknown
-
2016
- 2016-06-21 IL IL246367A patent/IL246367A0/en unknown
- 2016-06-24 MX MX2021004404A patent/MX2021004404A/es unknown
-
2021
- 2021-11-11 IL IL288023A patent/IL288023A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US10654933B2 (en) | 2020-05-19 |
KR20160102283A (ko) | 2016-08-29 |
CA3233584A1 (en) | 2015-07-02 |
MX2021004404A (es) | 2021-06-15 |
AU2014370873A1 (en) | 2016-07-14 |
WO2015099165A1 (ja) | 2015-07-02 |
TWI787590B (zh) | 2022-12-21 |
EP3088411A4 (en) | 2018-12-19 |
NZ722057A (en) | 2022-10-28 |
CA2935143C (en) | 2024-05-07 |
IL296754A (en) | 2022-11-01 |
CA2935143A1 (en) | 2015-07-02 |
TW201609790A (zh) | 2016-03-16 |
CN106029682B (zh) | 2021-04-13 |
RU2714967C2 (ru) | 2020-02-21 |
IL246367A0 (en) | 2016-08-31 |
JP6722455B2 (ja) | 2020-07-15 |
MX2016008498A (es) | 2016-10-07 |
EP3088411A1 (en) | 2016-11-02 |
SG11201605256YA (en) | 2016-08-30 |
CN106029682A (zh) | 2016-10-12 |
MY181081A (en) | 2020-12-17 |
TWI715524B (zh) | 2021-01-11 |
AU2014370873B2 (en) | 2020-06-11 |
TW202026304A (zh) | 2020-07-16 |
IL288023A (en) | 2022-01-01 |
JPWO2015099165A1 (ja) | 2017-03-23 |
KR102344170B1 (ko) | 2021-12-27 |
US20160326253A1 (en) | 2016-11-10 |
RU2016130664A (ru) | 2018-02-01 |
RU2016130664A3 (pt) | 2018-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016014824A2 (pt) | Método para purificar anticorpo que tem ponto isoelétrico baixo | |
CL2018002694A1 (es) | Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112) | |
BR112018075516A2 (pt) | purificação de anticorpos multiespecíficos | |
CY1122951T1 (el) | Φαρμακευτικα σκευασματα ενος αναστολεα υδροξυλασης ηιf | |
CY1121736T1 (el) | Άλατα aramchol | |
CL2015003731A1 (es) | Inhibidores de bromodominios | |
BR112015004467A2 (pt) | método para controlar a heterogeneidade de proteínas | |
EA201791424A1 (ru) | Получение белка | |
EA201291034A1 (ru) | АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ B-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ | |
BR112016010454A2 (pt) | métodos para tratar uma taupatia | |
SG10201811186XA (en) | Purification of proteins | |
PH12015501687A1 (en) | Novel binding proteins from pcsk9 | |
BR112015023447A2 (pt) | purificação de proteínas helicoidais triplas | |
EA201591791A1 (ru) | Антитела pac1 человека | |
BR112016001461A2 (pt) | Método ou processo para modificar a fucosilação em um sistema de expressão de proteínas eucariótico e/ou eucariote, glicoproteína, e, uso de uma glicoproteína | |
BR112016015718A2 (pt) | Processo de purificação de aminoácidos aromáticos | |
BR112017000135B8 (pt) | Processo para a preparação de ácidos 4-alcóxi-3-hidroxipicolínico | |
BR112017004231A2 (pt) | processo para produzir um precipitado estável enriquecido em ficobiliproteínas | |
BR112015027187A2 (pt) | processo de fabricação de uma composição antiperspirante aquosa e método de obtenção de um benefício de antiperspirância | |
CY1122640T1 (el) | Θεραπεια και προφυλαξη δερματιτιδας ακτινοβολιας | |
CL2016002546A1 (es) | Método para procesar una corriente hemicelulósica acuosa con un alcohol alquílico a temperatura elevada y ph ácido y separar la mezcla obtenida. | |
EA201690690A1 (ru) | Способ придания волосам определённой формы | |
EA201691563A1 (ru) | Сухой кислотный концентрат в гранулированной форме | |
EA201692038A1 (ru) | Способы и композиции для лечения сосудистой мальформации | |
EA201791423A1 (ru) | Способ получения белка |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023019769-0 PROTOCOLO 870230085483 EM 26/09/2023 15:37. |
|
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |